Clinical Trials Logo

Locally Advanced clinical trials

View clinical trials related to Locally Advanced.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03644056 Completed - Solid Tumor Clinical Trials

Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors

Start date: March 22, 2018
Phase: Phase 1
Study type: Interventional

This is a phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of IMC-001 in Subjects with Metastatic or Locally-advanced Solid Tumors

NCT ID: NCT01327612 Completed - Colorectal Cancer Clinical Trials

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Start date: March 3, 2011
Phase: Phase 2
Study type: Interventional

The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease progression whose previous studies were closed.

NCT ID: NCT01216345 Completed - Locally Advanced Clinical Trials

Cetuximab + Gemox in Biliary Tract Cancer

Start date: October 2006
Phase: Phase 2
Study type: Interventional

The aim of this prospective single-centre phase II study is to investigate the therapeutic efficacy and safety of cetuximab in combination with Gemcitabine and Oxaliplatin (GEMOX) in the palliative first line treatment of biliary tract cancer (BTC) patients.

NCT ID: NCT00911170 Completed - Cancer Clinical Trials

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Start date: November 3, 2009
Phase: Phase 3
Study type: Interventional

This is a phase 3, randomized, double-blind, placebo-controlled multi-center study evaluating the efficacy of pegfilgrastim to reduce the incidence of febrile neutropenia (FN) in patients with newly diagnosed, locally-advanced or metastatic colorectal cancer receiving first-line treatment with bevacizumab and either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI). This study will also investigate the effect of adding pegfilgrastim to bevacizumab and either FOLFOX or FOLFIRI by evaluating overall survival, progression-free survival, and overall response rate in each arm at regular intervals over a maximum of 60 months follow-up.

NCT ID: NCT00378313 Completed - Breast Cancer Clinical Trials

A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer

Start date: November 2001
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to determine whether locally advanced breast cancer responds (by shrinking, by not progressing or by being destroyed) to combined chemotherapy (gemcitabine, epirubicin and paclitaxel) given before surgery to patients with locally advanced breast cancer. This study will also evaluate the toxicity of the chemotherapy combination to patients and will determine survival and progression-free survival 2 years after treatment. Also, the study will look at whether there are molecular and genetic changes in the tumor tissue that match the tumor's response to the chemotherapy.